{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:09:18Z","timestamp":1724944158060},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.1097\/qai.0b013e318209740f","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T08:03:23Z","timestamp":1297411403000},"page":"S3-S6","source":"Crossref","is-referenced-by-count":27,"title":["A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care"],"prefix":"10.1097","volume":"56","author":[{"given":"Laura W","family":"Cheever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F","family":"Kresina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adan","family":"Cajina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lubran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210131","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.drugalcdep.2006.12.002","article-title":"Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women.","volume":"89","author":"Cook","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R3-2-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/apc.2009.0242","article-title":"Integrated opioid disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agoinst theapies.","volume":"24","author":"Batkis","year":"2010","journal-title":"AIDS Patient Care STD"},{"key":"R4-2-20210131","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1037\/a0013637","article-title":"Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.","volume":"16","author":"Mendelson","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"R5-2-20210131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jsat.2006.10.005","article-title":"Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.","volume":"32","author":"Basu","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R6-2-20210131","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1300\/J069v26n02_03","article-title":"Outcomes of buprenorphine maintenance in office-based practice.","volume":"26","author":"Magura","year":"2007","journal-title":"J Addict Dis"},{"key":"R7-2-20210131","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.","volume":"22","author":"Moore","year":"2007","journal-title":"J Gen Intern Med"},{"key":"R8-2-20210131","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.","volume":"37","author":"Soeffing","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R10-2-20210131","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.drugpo.2006.10.004","article-title":"Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America.","volume":"18","author":"Friedman","year":"2007","journal-title":"Int J Drug Policy"},{"key":"R11-2-20210131","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jurban\/jth125","article-title":"Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users.","volume":"81","author":"Friedman","year":"2004","journal-title":"J Urban Health"},{"key":"R14-2-20210131","first-page":"1","article-title":"Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Soc.","volume":"52","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"R15-2-20210131","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00005650-200001000-00007","article-title":"Prevalence and predictors of unmet need for supportive services among HIV-infected persons: impact of case management.","volume":"38","author":"Katz","year":"2000","journal-title":"Med Care"},{"key":"R16-2-20210131","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.euroneuro.2003.08.005","article-title":"Neuroadaptive mechanisms of addiction: studies on the extended amygdale.","volume":"13","author":"Koob","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R18-2-20210131","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/157016209788680598","article-title":"Medication assisted treatment in the treatment of drug abuse and dependence in HIV\/AIDS infected drug users.","volume":"7","author":"Kresina","year":"2009","journal-title":"Curr HIV Res"},{"key":"R19-2-20210131","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions.","volume":"64","author":"Compton","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R20-2-20210131","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1086\/500200","article-title":"Models for integrating buprenorphine therapy into the primary HIV care setting.","volume":"42","author":"Basu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R21-2-20210131","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1360-0443.2008.02216.x","article-title":"Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients.","volume":"103","author":"Hanson","year":"2008","journal-title":"Addicition"},{"issue":"Suppl 1","key":"R23-2-20210131","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/QAI.0b013e3182097426","article-title":"Egan JE, et al; BHIVES Collaborative. Integration of buprenorphine\/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e318209740f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:52:53Z","timestamp":1620971573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201103011-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":17,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318209740f","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}